PRIMARY CARE MANAGEMENT OF OBESITY

Similar documents
Medical Management of Obesity: Multidisciplinary Team and Pharmacologic Therapy. Shelby Sullivan University of Colorado School Of Medicine

ANTIPSYCHOTIC POLYPHARMACY

Michael J. Bailey, M.D. OptumHealth Public Sector

EARLY ONSET SCHIZOPHRENIA

Anti-Obesity Agents Drug Class Prior Authorization Protocol

Index. Note: Page numbers of article titles are in boldface type. A ADHD. See Attention-deficit/hyperactivity disorder (ADHD) b-adrenergic blockers

More than We Bargained For: Metabolic Side Effects of Antipsychotic Medications

Aggression (Severe) in Children under Age 6

WHICH BIPOLAR MEDS TO USE IN PRIMARY CARE?

Obesity Management in Patients with Diabetes Jamy D. Ard, MD Sunday, February 11, :15 a.m. 11:00 a.m.

Losing weight (and keeping it off) calls for changes to how you live your life, as well as to your connection to food and exercise.

The Brain and the Body: Medical Comorbidities in Psychiatric Illness. Kate Miley, CNP Psychiatric Nurse Practitioner, HCMC Adult Psychiatry Clinic

Measure #383 (NQF 1879): Adherence to Antipsychotic Medications For Individuals with Schizophrenia National Quality Strategy Domain: Patient Safety

See Important Reminder at the end of this policy for important regulatory and legal information.

Practical Psychopharmacology for More Complex Mental Health Presentations

Clinical Update on the Management of Schizophrenia

Class Update: Oral Antipsychotics

OBESITY 2008: DIET, EXERCISE, DRUGS, AND SURGERY

Disclosures OBESITY. Overview. Obesity: Definition. Prevalence of Obesity is Rising. Obesity as a Risk Factor. None

Faculty/Presenter Disclosure

Measure #383 (NQF 1879): Adherence to Antipsychotic Medications For Individuals with Schizophrenia National Quality Strategy Domain: Patient Safety

SCHIZOPHRENIA. For Primary Care Providers. Project ECHO LA Adult Psychiatry ECHO June 25, 2014

The New Trend of Anti-Obesity Drug

Overweight and Obesity on the Menu. Marwan Akel, Pharm. D, MPH Clinical Assistant Professor School of Pharmacy Lebanese International University

Cardiometabolic Risk Factors and Antipsychotic Medications Changing Prescribing Practices Promoting Wellness

What is obesity? OBESITY. Obesity is a health issue in which someone has so much extra fat that it negatively impacts their health.

Meccanismi fisiopatologici e trattamento dei disturbi metabolici in soggetti affetti da disturbo mentale grave

Introduction. Objectives. Psychotropic Medications & Cardiometabolic Risk

Bariatric Surgery: Indications and Ethical Concerns

Pregnancy. General Principles of Prescribing in Pregnancy (The Maudsley, 12 th Edition)

Part 1: Obesity. Dietary recommendations in Obesity, Hypertension, Hyperlipidemia, and Diabetes 10/15/2018. Objectives.

Antipsychotics. Something Old, Something New, Something Used to Treat the Blues

Metabolic Syndrome. Shon Meek MD, PhD Mayo Clinic Florida Endocrinology

Antipsychotic-Related Risk for Weight Gain and Metabolic Abnormalities During Development Christoph U. Correll, MD

Clinical Guideline for the Management of Bipolar Disorder in Adults

Treatment of Obesity: Diets, Drugs and Surgery

Healthy weight 18.5 to <25. Diabetes Dispatch. Overweight 25 to <30. Obese class I 30 to <35. Obese class II 35 to <40

University of Groningen

Obesity Clinical Practice Guidelines Where we are and where we re going! Donna H. Ryan, MD

MEDICATION ALGORITHM FOR ANXIETY DISORDERS

Minimising the Impact of Medication on Physical Health in Schizophrenia

ANXIETY: FAST FACTS AND SKILLS FOR THE PRIMARY CARE PHYSICIAN

Kelly E. Williams, Pharm.D. PGY2 Psychiatric Pharmacy Resident April 16,2009

Your footnote

New Patient Questionnaire

Dietary recommendations in Obesity, Hypertension, Hyperlipidemia, and Diabetes. Stephen D. Sisson MD

Eligible Beneficiaries

BLONANSERIN. THERAPEUTICS Brands Lonasen see index for additional brand names

Quetiapine Case 1 Warfarin Jose de Leon, MD

Re: Safety data on Zyprexa (olanzapine) and Symbyax (olanzapine and fluoxetine HCl capsules) Hyperglycemia, Weight Gain, and Hyperlipidemia

WHEN AND HOW TO USE BENZODIAZEPINES IN TREATING ANXIETY: AM I WITHHOLDING TREATMENT IF I DON'T USE BENZODIAZEPINES?

SAMPLE REPORT MENTAL HEALTH DNA INSIGHT LABORATORY INFO. Protected Health Information. SSRIs. TCAs. Other Antidepressants

USE OF BUPRENORPHINE FOR CHRONIC PAIN

11/11/2016. Disclosures. Natural history of BPSD. Objectives. Assessment of BPSD. Behavioral Management of Persons with Alzheimer s Disease

Conflict of Interest Disclosure Obesity Treatment: What Is a Staged Approach & What Does it Mean for Clinicians?

Management of Obesity. Objectives. Background Impact and scope of Obesity. Control of Energy Homeostasis Methods of treatment Medications.

PDF created with pdffactory Pro trial version

Clozapine Case 6: Half-Life Jose de Leon, MD

Engaging Pharmacotherapy and Behavioral Interventions to Maximize Post-Procedure Weight Loss

Things You Might Not Know About Psychotropic Medications But Wish You Did

Other Ways to Achieve Metabolic Control

Pharmacotherapy of psychosis and schizophrenia in youth

BIPOLAR DISORDERS DIAGNOSTIC AND TREATMENT ISSUES RICHARD RIES MD

STEP THERAPY CRITERIA

Quetiapine Case 2 Therapeutic Drug Monitoring Jose de Leon, MD

Disclosure Statement. A Rational Approach to Psychopharmacology. Goals 10/28/2013

Comorbid Conditions and Antipsychotic Use in Patients with Depression

Treatment of Bipolar disorder

Manual of Clinical Psychopharmacology

Objectives. Disclosure of Commercial Support. Psychopharmacology and Pediatric Obesity

Pharmacists in Medication Adherence in Psychiatric Patients

Bariatric surgery: Impact on Co-morbidities and Weight Loss Expectations ALIYAH KANJI, MD FRCSC MIS AND BARIATRIC SURGERY SEPTEMBER 22, 2018

Overall Implementation Strategy/Focus:

Bipolar Disorder Michael Coudreaut, MD

Bipolar Disorder in Youth

Kelly Godecke, MD Department of Psychiatry University of Utah

Supplementary Online Content

Strategies to Prevent Weight Gain Among Adults. Presented by Susan Hutfless, PhD Johns Hopkins University

Recent Advances in the Antipsychotic Treatment of People with schizophrenia. Robert W. Buchanan, M.D.

Primary Outcome Results of DiRECT the Diabetes REmission Clinical Trial

ASENAPINE. THERAPEUTICS Brands SAPHRIS see index for additional brand names

Weight management IN ADULTS ASSESS MANAGE MONITOR MAINTAIN. Proceed to stage 2: Assess. Reassess. Obese. Overweight

THE EVOLUTION OF MAN homo lethargicus gigantico

Using New Guidelines to Improve Best Practices in Obesity Management

OPIOIDS: ENGAGING PATIENTS IN OUD TREATMENT

UC San Francisco UC San Francisco Previously Published Works

What s new in the treatment of bipolar disorder?

Mr. E, age 37, has a 20-year history

A Bariatric Patient in my Waiting Room: Choosing the Right Patient for the Right Operation: Bariatric Surgery Indications

Life Goals Collaborative Care

Aggression (Severe) in Children under Age 6

Medication Audit Checklist- Antipsychotics - Atypical

Risperidone Case 1: Drug-Drug Interactions

The prevalence of obesity in adults has doubled over the past 30 years

Prevalence of Obesity (Adults) Prevalence of Obesity (Children) CURRENT STRATEGIES IN. Obesity: 33.8% Men: 32.2% Women: 35.5%

Obesity Management in Type 2 Diabetes

Randy Wexler, MD, MPH Associate Professor and Clinical Vice Chair Department of Family Medicine The Ohio State University Wexner Medical Center

Update in Obesity: the 10 Most Interesting Studies in DGIM Grand Rounds January 26, 2010

Interactions between Antiepileptics and Second- Generation Antipsychotics

SOUND HEALTH & WELLNESS TRUST

Transcription:

Psychiatry and Addictions Case Conference UW Medicine Psychiatry and Behavioral Sciences PRIMARY CARE MANAGEMENT OF OBESITY LYDIA CHWASTIAK MD, MPH ASSOCIATE PROFESSOR UNIVERSITY OF WASHINGTON DEPARTMENT OF PSYCHIATRY AND BEHAVIORAL SCIENCES MARCH 22, 2018

GENERAL DISCLOSURES The University of Washington School of Medicine also gratefully acknowledges receipt of educational grant support for this activity from the Washington State Legislature through the Safety-Net Hospital Assessment, working to expand access to psychiatric services throughout Washington State.

SPEAKER DISCLOSURES Nothing to disclose

OBJECTIVES 1. Consider assuming a larger role in prevention and management of obesity, especially among patients with serious mental illness 2. Learn specific strategies for brief counseling within clinic visits 3. Understand the effectiveness of behavioral lifestyle modification and pharmacologic treatments for obesity

EPIDEMIOLOGY OF OBESITY 2011-2014: 68% of US adults are overweight; 36.5% are obese 2 nd leading cause of preventable death $147 billion in medical costs http://www.cdc.gov/obesity/data/adult.html

APA/AMP 2017: Primary Care Skills for Psychiatrists DEFINITION OF OBESITY BMI NIH Cutoff Asian- American Ideal 18.5-24.9 18.5-22.9 Overweight 25-29.9 23-26.9 Obesity 30-34.9 >=27 Class I Class II 35-39.9 Class III >=40 Waist Circumference Male NIH 102 cm Asian- Amer 90 cm Female 88 cm 80 cm

EVIDENCE-BASED TREATMENTS Lifestyle modification Pharmacologic Treatment Surgical Patient and Family Education Behavioral Counseling Lifestyle Modification Exercise Interventions Diet Interventions Standard pharmacologic treatment Antipsychotic Switching Bariatric surgery AHRQ Publication No. 12-EHC063-EF; April 2013

5 A APPROACH Assess Physical activity level Physical abilities Beliefs and Knowledge Advise Health risks Beliefs of change Appropriate dose of physical activity Agree Co-Develop personalized action plan Set specific physical activity goals based on interests and confidence level Assist Identify barriers and create strategies to address them Identify resources for physical activity and social support Arrange Specify plan for follow-up Check on progress/ maintenance of change AuYoung, M., et al. Am J Med, 129(10), 1022-1029.

EXERCISE IS MEDICINE (2007) 2010 National Health Interview Survey: < 1/3 of all adults who visited a physician in the last year were advised by their physician to start or continue exercising EIM Goal: Physical activity assessment and exercise prescription a standard part of the disease prevention for all patients Assess: Physical activity as a vital sign Barnes, P. a. S., CA. (2012). https://www.cdc.gov/nchs/data/databriefs/db86.htm. Sallis, R. (2015). Phys Sportsmed, 43(1), 22-26.

PRESCRIPTION FOR EXERCISE Advise: 2-3 minutes Prescription Frequency Intensity Type Time a simple exercise prescription would be to advise the patient to walk 30 minutes at a brisk pace on 5 days each week.

MAKE A SPECIFIC PLAN The more detailed the plan, the more likely it will be followed. In the plan, consider: Date or days of the week What time of day How long With whom Other aspects that need to be planned Ask patient How likely are you to do this?

BUILDING SUCCESS It s an experiment, a trial, it s not forever Suggest they act first and see what happens Praise any success they make Go slow and start small Reframing failure is essential

COUNSELING ABOUT DIET 44 RCT, 18,000+ participants Outcomes Reduce salt Reduce fat Increase vegetables Increase fiber Rees K, et.al. Cochrane 2013, Issue 12. CD002128.

CHOOSEMYPLATE.GOV Read the labels: compare sugar Make half your plate vegetables and fruits Vary your protein

LIFESTYLE MODIFICATION Diabetes Prevention Program (n= 3,234 at 27 centers) 1 RCT, 3 arms: metformin, placebo, lifestyle modification Training and support--goals loss of 7% of initial body weight 150 minutes of physical activity per week Lifestyle group reduced 3-year risk of developing diabetes by 58% (metformin by 31%) Widely disseminated into community settings 2 1 Diabetes Prevention Program Group, N Engl J Med 2002; 346(6): 393-403. 2 Ali MK et al. Health Affairs 2012; 31(1): 67-75.

EFFECTIVENESS IN SERIOUS MENTAL ILLNESS IN SHAPE (n=133) Physical Activity, nutrition and smoking Improved fitness at 3,6,9,12m ACHIEVE (n=291) 18 months: individual + group exercise, nutrition 37.8% lost >5% IBW (compared to 22.7% of control, p = 0.0009) STRIDE (n=200) 12 months (6 +6 months) physical exercise, food records, personalized plans, cognitive strategies 40% lost >5% BW c/w 17% controls (p=0.001) at 6 months Daumit GL et al. N Engl J Med 2013; 368: 1594-1602 Green CA et al. Am J Psychiatry Am J Psychiatry. 2015 Jan;172(1):71-81 Bartels SJ, et. al. Psychiatr Serv 2013; 64(8): 729-736

BEHAVIORAL WEIGHT LOSS INTERVENTIONS Most likely to be effective: Longer duration (24 weeks) Manualized Combined education and activity Both nutrition and physical exercise Evidence-based (proven effective by RCTs) Less likely to be successful: Briefer duration interventions General wellness or health promotion education-only Non-intensive, unstructured, or non-manualized interventions Bartels S, et al. SAMHSA-HRSA Center for Integrated Health Solutions, UW 2012 PACC

Metabolic Liability of Medications Low risk Moderate risk High risk Carbamazepine Mirtazapine Lithium Lamotrigine Paroxetine Valproate Oxcarbazepine Paliperidone Olanzapine Aripiprazole Asenapine Clozapine Lurasidone Iloperidone Ziprasidone Paliperidone Quetiapine Risperidone Hasnain M et al. Postgraduate Med 2013; 125 (5): Werneke U, Taylor D, Sanders TA. Curr Psychiatry Rep; 2013; 15: 347

SWITCH TO REDUCE METABOLIC RISK (CAMP) 0 0 Weight change (kg) -0.5-0.5-1 -1.0-1.5-1.5-2 -2.0-2.5-2.5-3 -3.0-3.5-3.5 Stay Switch -4-4 4 8 12 16 20 24 Stroup TS, et al. Am J Psychiatry 2011; 168: 947-956 Week of visit

PHARMACOTHERAPY Agent Evidence in schizophrenia Metformin 3 kg weight loss at 16 weeks 1 *Phentermine-Topiramate Topiramate: 5 kg weight loss *Orlistat +/- *Lorcaserin None *Naltrexone/Bupropion +/- *Liraglutide None * FDA approval for weight loss Jarskog LF, et al. Am J Psychiatry 2013; 170:1032-1040 Das C, et al. Annals of Clinical Psychiatry 2012; 24(3): 225-239

BARIATRIC SURGERY Indications based on current guidelines Class III obesity (BMI > 40 kg/m2) Class II obesity (BMI = 35-39.9) with medical complication (DM, Sleep apnea) Class I obesity with poorly-controlled T2 DM Mean BMI of those having procedures is > 45 NHLBI, NIH Publication No. 98-4083, 1998 Buchwald H et al JAMA 2004; 292 (14): 1724-1737

BARIATRIC SURGERY Indications based on current guidelines Class III obesity (BMI > 40 kg/m2) Class II obesity (BMI = 35-39.9) with medical complication (DM, Sleep apnea) Class I obesity with poorlycontrolled T2 DM Mean BMI of those having procedures is > 45 Change in BMI 0-2 -4-6 -8-10 -12 0 3 6 9 12 Months Medical RYGB SG NHLBI, NIH Publication No. 98-4083, 1998 Buchwald H et al JAMA 2004; 292 (14): 1724-1737 Schauer PR, et al. N Engl J Med 2012; 366: 1567-1576

QUESTIONS?